GLP-1 is a hormone your gut releases after a meal. It tells the pancreas to make insulin, slows how fast your stomach empties, and signals fullness to your brain. So what is GLP-1 as a medication? It is a lab-made copy of that hormone, engineered to last for days instead of minutes, which is why one weekly shot can steady blood sugar and quiet appetite. That single idea explains almost everything about this drug class.
What does the natural hormone actually do?
The full name is glucagon-like peptide-1. Your intestine puts it out in response to food, and it acts in several places at once. It boosts insulin only when blood sugar is high, so it rarely drives sugar too low on its own. It slows stomach emptying, which stretches out the feeling of being full. And it works on brain regions tied to appetite, which is the part most people notice.
The catch with the real hormone is that it disappears within minutes. Enzymes break it down almost as fast as it appears. The whole science of these drugs is about redesigning the molecule so the body cannot clear it quickly, turning a fleeting signal into one that lasts a week. A 2024 review in the pharmacology literature lays out how single and dual receptor agonists produce these effects across metabolism.
How do the medications copy it?
There are two broad approaches. The first is a peptide that resembles the natural hormone but resists breakdown, given as a weekly injection. Semaglutide is the best known example. The second is a newer approach that pushes on more than one receptor at a time. Tirzepatide hits both the GLP-1 receptor and the GIP receptor, a related gut hormone; the discovery work behind that dual molecule was published in 2018 and it turned into one of the stronger agents in the class.
A third route is a small molecule you can swallow. Orforglipron is an oral GLP-1 receptor agonist, and early trial data in adults with obesity appeared in 2023. It was later approved by the FDA in 2026 under the brand name FOUNDAYO for weight management, a milestone summarized in the “First Approval” report and the 2025 phase-three obesity results. Investigational agents such as retatrutide are still being studied and are not approved for anyone yet.
Which GLP-1 medications compare against which?
| Approach | Example | Form | Status |
|---|---|---|---|
| GLP-1 receptor agonist (peptide) | Semaglutide | Weekly injection | FDA-approved |
| Dual GIP and GLP-1 agonist | Tirzepatide | Weekly injection | FDA-approved |
| Oral small-molecule GLP-1 agonist | Orforglipron (FOUNDAYO) | Daily pill | FDA-approved in 2026 |
| Triple agonist | Retatrutide | Injection (study) | Investigational |
These sit on a rough ladder of strength, but the numbers come from separate trials with different designs, not head-to-head matchups. Reading one drug’s percentage next to another’s is a starting point, not a verdict. A prescriber weighs the target condition, side effects, and whether a pill or a shot fits the person better.
What do the trials show about weight and blood sugar?
The short answer is that the effect is real and, for the stronger agents, larger than earlier weight-loss drugs. Studies of the newer molecules have reported average reductions well into the double digits as a percentage of body weight over roughly a year or more. The important word is average. Some people respond strongly, some modestly, and the effect tends to fade if the medication stops, because the appetite signal it was supplying goes away.
Blood sugar improvement was the original point of the class, and it remains a core use. Beyond diabetes and weight, GLP-1 based treatment is being studied in related metabolic conditions, including fatty liver disease, which the 2024 European guidelines on metabolic dysfunction-associated steatotic liver disease address in detail.
Who are these drugs meant for?
Current obesity treatment guidelines, including the 2025 clinical practice update and the AGA guideline on drug therapy for obesity, place GLP-1 medications among the more effective pharmacological options, typically for adults meeting body mass index thresholds or those thresholds plus a weight-related condition. A separate 2025 effort has worked to redefine clinical obesity around actual organ and tissue effects rather than a single number, which reflects how the field is moving past BMI alone.
What these guidelines do not say is that everyone with a few pounds to lose should be on one. These are prescription medications with real gastrointestinal side effects, real cost, and a tendency to reverse when discontinued. For someone at the lower end of the spectrum with no metabolic complications, the honest answer is often that the trade is not worth it.
What about cost and the compounded versions?
List prices for the brand injectables run above a thousand dollars a month, and coverage is uneven because many plans exclude weight-management drugs as a category. That gap is why several access routes exist. Manufacturer self-pay programs from Novo Nordisk and Eli Lilly, delivered through channels like LillyDirect and NovoCare, sell brand medication to cash payers below list. Telehealth services such as Ro, Hims and Hers, and Henry Meds bundle prescribing with delivery.
Compounded semaglutide and tirzepatide are a different thing. They are prepared by compounding pharmacies and are not FDA-approved products, which means they have not been through the process behind the trial evidence discussed above. Some physician-supervised telehealth practices, including FormBlends, publish flat monthly pricing for compounded options, and a plain reading of what GLP-1 actually does helps explain why the molecule matters more than the label to some patients weighing that choice. The predictable cash price is the appeal; the missing regulatory assurance is the cost. That trade belongs with a prescriber who knows the case, not a checkout page.
See also: Why Hiring a Personal Accident Lawyer Matters After an Injury in Denver
Key takeaways
- GLP-1 is a natural gut hormone; the drugs are longer-lasting copies that steady blood sugar and reduce appetite.
- Dual agonists like tirzepatide add a second receptor; orforglipron is an approved oral option as of 2026.
- Trial results are averages from separate studies, so cross-drug comparisons are rough, not definitive.
- Compounded versions are not FDA-approved, and that distinction is real, not a formality.
Frequently asked questions
What is GLP-1 in the simplest terms?
GLP-1 is a hormone your gut releases after you eat. It nudges the pancreas to release insulin, slows how fast the stomach empties, and signals fullness to the brain. GLP-1 medications copy that natural hormone and make its effects last much longer.
Are GLP-1 drugs only for diabetes?
No. The class started in type 2 diabetes, but several GLP-1 based medications are now approved for chronic weight management, and guidelines list them among the more effective drug options for obesity.
Is a pill version available?
Yes. Orforglipron, brand name FOUNDAYO, is an oral small-molecule GLP-1 receptor agonist that received FDA approval in 2026 for weight management. Most other approved GLP-1 medications are weekly injections.
Is compounded GLP-1 the same as the brand?
No. Compounded versions are prepared by a compounding pharmacy and are not FDA-approved products. They may contain the same active molecule, but they have not gone through the approval process tied to the published trial evidence.
How much weight do these medications actually cause?
It varies by drug and person. Trials of the stronger agents have reported average reductions well into the double digits as a percentage of body weight, but results depend on dose, duration, and continued use.
